Please login to the form below

Not currently logged in

J&J bolsters gene therapy unit with $100m MeiraGTx deal

Licenses two inherited retinal disorder candidates


Johnson & Johnson has made its biggest move into gene therapy, signing a $100m deal with UK-headquartered biotech MeiraGTx for rights to two genetic eye diseases programmes.

J&J is licensing candidates for two inherited retinal disorders – achromatopsia (ACHM) caused by mutations in either CNGB3 or CNGA3, and X-linked retinitis pigmentosa (XLRP) – which are in phase 1/2 clinical trials.

ACHM is a non-progressive condition characterised by partial or total absence of colour vision, while XLRP, caused by mutations in the RPGR gene, leads to progressive vision loss.

In addition to the $100m upfront payments, J&J’s Janssen division is proffering up to $340m in additional payments if the programs progress towards the market, plus royalties on any future sales, and has agreed to fund clinical trials.

In return it has claimed worldwide rights to the gene therapies, which represent a sizeable chunk of MeiraGTx’ clinical pipeline, as well as taking an option on preclinical-stage follow-ups for inherited retinal disorders. MeiraGTx is also working on gene therapies for salivary gland problems and neurodegenerative diseases.

The companies will also work together on new targets for other inherited retinal diseases and on adeno-associated virus (AAV) manufacturing technology.

J&J has made some small investments in gene therapies over the last few years, but this is its biggest move to date, and comes after it started working with MeiraGTx last year on a project looking at using the biotech’s riboswitch technology – essentially an on-off switch for delivered genes – to engineer “regulatable” gene therapies.

J&J’s earlier forays into this area include a collaboration with the University of Pennsylvania on an Alzheimer’s programme, announced in early 2018.

The deal comes at a time when gene therapies finally seem to be about to fulfil their promise, after decades of research.

In Europe, the first approved gene therapy – UniQure’s Glybera – was launched way back in 2012 but was withdrawn five years later for commercial reasons. GlaxoSmithKline launched its Strimvelis product in 2016, but sold it to Orchard Therapeutics last year after opting to exit the rare disease category.

The US market developed a little later, with Spark Therapeutics’ Luxturna (voretigene neparvovec) for biallelic RPE65-mediated inherited retinal disease claiming FDA approval at the end of 2017, with a green light in Europe – where it will be sold by Novartis – coming through last year.

Another gene therapy, Novartis’ Zolgensma for spina muscular atrophy, is heading for regulatory decision in the US this year and in Europe in 2020.

Article by
Phil Taylor

1st February 2019

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
JPA Health Communications

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

WHITE PAPER: The increasing importance of clinical trial marketing advertising in patient recruitment
Learn why advertising is more important than ever in clinical studies...
The 'winner takes all' pricing game
Tendering has long been common in healthcare for medical devices and diagnostics; the Gulf Cooperation Council and the Jamaica Commodity Trading Company have been using pharmaceutical tendering since the 1970s....
Early diagnosis underpins NHS cancer strategy
Paul Midgley, Oli Hudson and Sarah Shield, of Wilmington Healthcare, explore how the NHS is tackling cancer in line with the Long-term Plan...